Apalutamide: A Cause of Neutropenic Sepsis.

Prostate cancer is one of the most frequently diagnosed cancers and poses a significant health burden. New androgen-targeted therapies are now standard treatments for various stages of prostate cancer, including hormone-sensitive, metastatic, and non-metastatic castration-resistant types. These therapies are generally well tolerated and often have fewer side effects compared to traditional chemotherapy.

Diagnostic challenge: pancreatic cancer masked by peripancreatic fluid collection after acute pancreatitis.

Pancreatic cancer (PC) manifests as a highly aggressive neoplastic growth, ranking as the fourth major contributor to cancer-related mortality in the United States. Despite sustained efforts, the incidence of PC is projected to rise, and the mortality rate has seen only a marginal reduction over time. A mere 15% of pancreatic cancer cases are deemed resectable upon presentation, explaining the notably low 5-year survival rate associated with this malignancy.

Low intensity mechanical signals promote proliferation in a cell-specific manner: Tailoring a non-drug strategy to enhance biomanufacturing yields.

Biomanufacturing relies on living cells to produce biotechnology-based therapeutics, tissue engineering constructs, vaccines, and a vast range of agricultural and industrial products. With the escalating demand for these bio-based products, any process that could improve yields and shorten outcome timelines by accelerating cell proliferation would have a significant impact across the discipline. While these goals are primarily achieved using or strategies, harnessing cell mechanosensitivity represents a promising - albeit less studied - pathway to promote bioprocessing endpoints, yet identifying which mechanical parameters influence cell activities has remained elusive.

Clinical and demographic factors modify the association between plasma phosphorylated tau-181 and cognition.

Introduction: Plasma phosphorylated tau-181 (p-tau181) associations with global cognition and memory are clear, but the link between p-tau181 with other cognitive domains and subjective cognitive decline (SCD) across the clinical spectrum of Alzheimer's disease (AD) and how this association changes based on genetic and demographic factors is poorly understood.

Methods: Participants were drawn from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and included 1185 adults >55 years of age with plasma p-tau181 and neuropsychological test data. Linear regression models related plasma p-tau181 to neuropsychological composite and SCD scores with follow-up models examining plasma p-tau181 interactions with cognitive diagnosis, apolipoprotein E ε4 carrier status, age, and sex on cognitive outcomes.